Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

November 4, 2021

Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021

October 29, 2021

Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress

October 4, 2021

Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder

September 17, 2021

Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

September 3, 2021

Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

August 10, 2021

Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results

August 5, 2021

Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021

July 27, 2021

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 20, 2021

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

June 15, 2021

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting

«...9 101112 13 14...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top